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chemotherapy after the index date to the earliest of mean time to HSCT, death, loss 
to follow-up, or last chemotherapy dose plus 30 days. The primary endpoint was 
the percent of time in the hospital during the salvage chemotherapy period. Key 
secondary endpoints were number of hospitalisations and length of hospital stay. 
Hospitalisations associated with HSCT were excluded. Results are presented as 
mean (SD) unless indicated. Results: Twenty-two patients were included, with 
a mean age of 44 (18) years. After the index date, 19 patients died and 8 patients 
received a HSCT. During the chemotherapy salvage period, patients spent a mean 
of 56% (95% CI: 46%-69%) of their time in the hospital. There were a mean of 2.2 
(1.5) inpatient hospitalisations, 3.2 (6.2) day stays, and 1.6 (3.0) outpatient visits per 
patient, and the mean length of inpatient hospitalisation was 20.0 (20.0) days. From 
the index date to death, there were a mean of 2.8 (1.4) inpatient hospitalisations, 
4.7 (7.3) day stays, and 4.6 (7.4) outpatient visits per patient and the mean length 
of inpatient hospitalisation was 19.0 (19.0) days. ConClusions: Adult patients 
receiving salvage chemotherapy for R/R ALL in Italy spend more than half their time 
in the hospital. Costs of hospitalisations will be presented.
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objeCtives: The goal of the study was to evaluate clinical and economic feasibil-
ity of nilotinib in comparison with the imatinib usage as the first-line therapy for 
chronic myeloid leukaemia (CML), and implementation of nilotinib compared with 
imatinib in high doses in the second-line treatment. Methods: Health-economic 
analysis and budget impact analysis of the use of tyrosine kinase inhibitors (TKI) for 
CML treatment were performed in Russian economic conditions. Economic models 
for the first and the second lines of CML treatment were built separately. Results: 
Analysis showed that use of nilotinib for patients with newly diagnosed CML as the 
first-line treatment and for patients with imatinib resistance or intolerability as 
the second-line treatment is accompanied by 36% increase of consolidated budget 
expenditures in 2015 compared to 2014 in theoretical consumption calculations. In 
terms of real consumption, use of nilotinib leads to 16% increase in consolidated 
budget expenditures in 2015, in comparison with 2014. Expected budget expenditure 
in 2015, taking into account actual consumption, is 5.8 billion RUB. The growth of 
state expenditure for CML treatment might be due to increase in the number of 
patients and the use of the second-generation TKI. In case of nilotinib use, with 
consideration of remission that allows therapy cancellation, the average cost of one 
CML patient treatment based on all lines of therapy in the registry per year will be 
decreased by 6% in 2018 compared to 2015, despite an increase in the number of 
patients in the registry. ConClusions: Nilotinib is characterized by greater effi-
ciency in the both lines of therapy. Using of the second-generation TKI, including 
nilotinib, can lead to stable remission with possible therapy cancellation after two 
or three years from the moment of deep molecular response. It may lead to the 
stabilization of cost per patient in the registry by 2018.
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objeCtives: To determine time spent in the hospital by adult R/R ALL patients 
treated with current salvage chemotherapies in Germany. Methods: Adult 
patients hospitalised between 2003 and 2014 for Ph-negative R/R ALL were 
included. Eligible patients were relapsed with first remission lasting less than 
12 months, relapsed after first salvage therapy, relapsed any time after HSCT or 
refractory to primary induction or salvage therapy. Data were collected from the 
index date (first diagnosis of R/R ALL) until death or loss to follow-up. The salvage 
chemotherapy period started at the first chemotherapy after the index date to the 
earliest of mean time to HSCT, death, loss to follow-up, or last chemotherapy dose 
plus 30 days. The primary endpoint was the percent of time in the hospital dur-
ing the salvage chemotherapy period. Key secondary endpoints were number of 
hospitalisations and length of hospital stay. Hospitalisations associated with HSCT 
were excluded. Results are presented as mean (SD) unless indicated. Results: 
Twenty-one patients were included, with a mean age of 44 (16) years. After the 
index date, 17 patients died and 10 patients received a HSCT. During the salvage 
chemotherapy period, the mean percent of time spent in the hospital by patients 
was 58% (95% CI: 41%-75%). There was a mean of 1.5 (1.4) inpatient hospitalisa-
tions per patient with no day stays or outpatient visits, and the mean length of 
inpatient hospitalisation was 25 (20) days. From the index date to death, there 
were 3.5 (6.3) inpatient hospitalisations, no day stays, and 0.2 (0.6) outpatient 
visits per patient and the mean length of inpatient hospitalisation was 20 (27) 
days. ConClusions: Adult patients receiving salvage chemotherapy for R/R ALL 
in Germany spend more than half their time in the hospital. Costs of hospitalisa-
tions will be presented.
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line; meanwhile PAMI cost are around USD 1.079, 66 for the first line and USD 815, 70 
for the second one. Sc first line is USD 192, 98 per minute and USD 73, 61 per minute 
the second line for IOMA and PAMI SC USD 174, 97 per minute for the first one and 
USD 66, 74 per minute for the second one. Ratio between IV RTX cost and application 
is for IOMA 1 L 19.62 % and 14, 82 % 2 L; for PAMI the ratio for IV first line is 17, 78 % 
and for 2L 13, 44 %. SC represents IOMA 1 L 3, 18 % and 2L 1, 21 %, For PAMI is 2, 88 % 
1L and 1, 10 % 2L. El ahorro nominal por tratamiento es de USD 997, 80 para IOMA y 
de USD 904, 69 PAMI. ConClusions: nominal saving are around USD 997 for IOMA 
and 904, 69 for PAMI for treatment. IV takes 5,30 as average meanwhile SC just 27 
minutes that could improve patients quality of life.
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objeCtives: To assess hospitalization costs of patients with spinal tumors in 
France. Methods: All hospital stays with spinal tumors were extracted from the PMSI-
MCO 2012 database (French Medical Information System Program- Medicine, Surgery, 
Obstetric): ICD-10 codes C41.2 or C41.4 or C41.8 as principal/related or significantly 
associated diagnosis for primary tumors; association of ICD-10 codes C79.5 and M49.5 
as principal/related or significantly associated diagnosis or M49.5 alone as principal/
related diagnosis for secondary tumors. Patients were followed during one year from 
their first stay (e.g. March 2012/March 2013). An algorithm and a medical review excluded 
non spinal tumor related stays. Associated costs during this period were added up: a 
total annual cost (“burden”) as well as a mean annual cost per patient were estimated. 
Valuation was performed considering French official tariffs for 2012 and 2013 expressed 
in 2014 Euro. Results: 9,415 stays were extracted and considered as directly related to 
spinal tumors corresponding to 3,284 patients. Patients were 66±19 years old on average, 
55% were female. 94% of stays occurred in public hospitals. 56% of stays were ambulatory 
(length of stay, LOS = 0 day) and mean LOS associated with full hospitalizations was 
11±14 days. Spine fracture management, chemotherapy and radiotherapy accounted 
for 30%, 30% and 28% of stays, respectively. Overall, the economic annual burden of 
hospitalizations for spinal tumor reason was € 26 million; expensive drugs and implants 
funded in addition to DRGs (diagnosis related groups) accounted for 6% of this burden. 
The mean annual cost was € 7,817±8,858 per patient. ConClusions: Spinal tumors 
are mainly managed in public hospital. Hospital-related costs associated with spinal 
tumors are high. New spinal tumors treatment modalities could decrease these costs.
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objeCtives: This retrospective chart review aimed to quantify hospitalisations and 
costs among adult R/R ALL patients treated with current salvage chemotherapies 
in France. Methods: Eligible patients were aged ≥ 18 years and hospitalised from 
2003-2013 for Ph-negative R/R ALL. They were relapsed with first remission lasting 
< 12 months, relapsed after first salvage therapy, relapsed any time after HSCT, or 
refractory to initial or salvage therapy. Data were collected from the index date (first 
diagnosis of R/R ALL) until death or loss to follow-up. The salvage chemotherapy 
period was defined as the first chemotherapy hospitalisation after the index date 
to the earliest of mean time to HSCT, death, loss to follow-up, or last chemotherapy 
dose plus 30 days. The primary endpoint was the percent of time in the hospital 
during the salvage chemotherapy period. A key secondary endpoint was total costs 
from index date to death. Hospitalisations and costs associated with HSCT were 
excluded. Results: Thirty-three patients were included, with mean age of 49 years 
(range 19-75). The mean proportion of time patients spent in the hospital during 
the salvage chemotherapy period was 46% (95%CI: 34%-57%). The mean number of 
inpatient hospitalisations during the salvage chemotherapy period was 2.15 (1.5), and 
mean length stay was 17 (15) days. During the salvage chemotherapy period, the mean 
(SD) cost per hospitalisation was € 31,067 (€ 4,850) and the mean hospitalisation cost 
per patient was € 66,842 (€ 46,268). From the index date to death, there was a mean of 
3.67 inpatient hospitalizations, 4.27 day hospitalizations, and 0.7 outpatient visits. 
Corresponding mean (SD) costs per hospitalisation were € 28,832 (€ 8,867), € 674 (0), and 
€ 394 (0) respectively, for a total cost per patient of € 108,967. ConClusions: Adult 
patients receiving salvage chemotherapy for R/R ALL spend approximately half their 
time in the hospital, which is associated with large reimbursement costs in France.
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objeCtives: To quantify hospitalisations among adult R/R ALL patients treated 
with current salvage chemotherapies in Italy. Methods: Adult patients hospital-
ised from 2003–2014 for Ph-negative R/R ALL were included. Eligible patients were 
relapsed with first remission lasting less than 12 months, relapsed after first salvage 
therapy, relapsed any time after HSCT or refractory to primary induction or salvage 
therapy. Data were collected from the index date (first diagnosis of R/R ALL) until 
death or loss to follow-up. The salvage chemotherapy period encompassed the first 
